The Canadian firm intends to commercialize a blood test that uses a nine biomarker metabolite panel and lab-based mass spectrometry to detect lung cancer at stages I and II.
Metabolomic Dx Prepares 2019 Launch of Preterm Preeclampsia Test, Eyes Broader Pregnancy Risk Panel
With European Union funds, the firm is accelerating its go-to-market strategy for the PrePsia four-metabolite, mass spec-based blood test for preterm preeclampsia.
Metabolomic Diagnostics Secures €2M to Support Commercialization of Preeclampsia Test
Its CEO said that the firm will use the funding to accelerate a go-to-market strategy, and that it plans to begin marketing the test next year.